Project COMET: Massed Prolonged Exposure for PTSD and SUD
Launched by RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY · May 5, 2025
Trial Information
Current as of September 08, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The clinical trial, called Project COMET, is studying a type of therapy known as Massed Prolonged Exposure Therapy (M-PE) to see if it can help people with Posttraumatic Stress Disorder (PTSD) who are also struggling with substance use disorders (SUD). The researchers want to find out if M-PE is better at reducing PTSD symptoms and the number of days people use substances compared to standard trauma treatment. They will also look at how this therapy affects overall well-being, including feelings of depression, thoughts of self-harm, and quality of life.
To participate in this trial, you need to be at least 18 years old and enrolled in substance use treatment at Gateway Community Services. You should meet the criteria for both SUD and PTSD. If you join, you’ll attend several therapy sessions each week and complete assessments at different points during and after treatment. The trial is not yet recruiting participants, but it offers a chance to contribute to important research that could improve treatment for others facing similar challenges.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 18+
- • Enrolled in SUD treatment at Gateway Community Services
- • Meet DSM-5 criteria for a SUD (Tobacco Use Disorder alone not sufficient for inclusion)
- • Meet DSM-5 criteria for PTSD
- • Able to give informed consent
- Exclusion Criteria:
- • severe cognitive impairment
- • current suicidal or homicidal intent requiring immediate treatment
- • current unstable psychotic or manic symptoms not attributable to SUD
About Rutgers, The State University Of New Jersey
Rutgers, The State University of New Jersey, is a prestigious public research university renowned for its commitment to advancing medical science and public health. As a leading clinical trial sponsor, Rutgers leverages its extensive academic resources, cutting-edge facilities, and a diverse team of experts to conduct innovative research that addresses critical health challenges. The university fosters collaboration across disciplines, engaging in partnerships with healthcare institutions and industry leaders to enhance the development of novel therapies and improve patient outcomes. With a strong emphasis on ethical standards and regulatory compliance, Rutgers is dedicated to advancing clinical knowledge while prioritizing participant safety and well-being in all of its research endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jacksonville, Florida, United States
Patients applied
Trial Officials
Sonya Norman Professor Of Clinical, Psychiatry, Ph.D
Principal Investigator
University of California, San Diego
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported